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ABSTRACT. As governments, industry bodies, and other interest groups
become more adept at influencing the conduct and dissemination of research,
it is increasingly important that the alcohol and other drug (AOD) sector
maintains and protects the integrity of its evidence base. This commentary
discusses the level and type of influence being exerted on the research pro-
cess by different interest groups within the field. It explores the impact and
influence of funding bodies, other interest groups, and social systems on
addiction and recovery using relevant examples to identify questions for
practitioners and researchers to consider when encountering interested par-
ties in their day-to-day practice. Ultimately, it is service users and clinicians
at the "front line" of recovery who have the most to lose from research
findings that have been unduly influenced. The best protection against bias
in these forms is to practice critical self-reflection and to keep openly and
honestly debating those things that we find most challenging.
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The control of knowledge has shaped human relations throughout his-
tory. Never has this been more the case than in this, the information age.
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Global initiatives for evidence-based models of service provision across the
health, social, and welfare sectors display often well-meaning yet some-
what naive motives to improve the lot for society's most vulnerable groups.
The study and treatment of alcohol and other drug (AOD)-related prob-
lems is a field of debate: abstinence vs. harm reduction; prohibition vs.
decriminalization; maintenance vs. detoxification and rehabilitation; or
"addiction" vs. rational choice, just to name a few. The field has so many
different strongly held opinions and preferred treatments that in the end,
it is vital that as the evidence base grows, we can have confidence in its
integrity (Edwards, 1993). Many of these debates have become polarized
and the knowledge base for how to deal with these problems has become
mired with the inertia of ideological conflict and self-interest. "Believers"
at either end of the spectrum in any of these debates often undermine
attempts to move the fieid forward by those who seek the middle road.
This commentary looks at the very small evidence base surrounding the
level and type of influence being exerted by different interest groups. It
also uses relevant examples to identify some questions for practitioners
and researchers to consider when encountering interested parties in their
day-to-day practice.
One of the major attempts to address this problem has been the advent
of "evidence-based practice," which has arisen from the evidence based
medicine (EBM) movement. EBM, as described by Wikipedia.com, "is
the conscientious, explicit, and judicious use of current best evidence in
making decisions about the care of individual patients." However, this ideal
has fallen on many difficulties as well, primarily revolving around whose
evidence is used, which types of evidence are acceptable or preferable, and
the quality or integrity of the evidence being presented (ter Meulen et al.,
2005). Critiques of evidence-based practice have highlighted issues such
as the lack of transportability from the research setting to clinical practice,
the oversimplification of clinical problems by research, and the skewing
of the evidence base away from the reality of clinical practice through
biases (such as research interest and funding body priorities). All of these
questions have boundless relevance for all who work within the AOD
sector and only scratch the surface. However, this commentary focuses on
the importance of integrity of the evidence base in the AOD sector, and in
particular, the way in which interest groups and funding bodies might be
biasing and adulterating the information we use to make crucial decisions
about drug policy, treatment regimes, and the basic ways in which we deal
with substance use in our communities.
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This is an issue that affects the whole of the AOD sector and should
be discussed by practitioners, researchers, policy makers, and ultimately
even substance users themselves. To do otherwise will further exacerbate
the divisions within the sector and create more bunkers, which impair
the community's ability to respond to alcohol- and drug-related problems.
These issues go far beyond simple research interest. They make the work
of taking substance users on the journey of recovery (regardless of defi-
nition) all the more difficult. In some ways, groups in recovery have the
most to lose from research findings that have been unduly influenced by
an interest group. Ideological disputes can reduce the chance of a patient
receiving the most effective combination of therapies. This journal's in-
augural edition highlighted the promising diversity of therapies that can
be used. Policy issues such as drug availability (be they legal or illegal),
advertising, and sponsorship can impact significantly on people's chances
of recovery, yet they seldom enter discussions around treatment effective-
ness. For example, the recent decision by the European Union to ignore
commissioned research (Anderson & Baumberg, 2006) because of pres-
sure from the alcohol industry will have significant impact on the size
of alcohol-related problems in the community but also on the ability of
prevention and treatment agencies to deal with the consequences (McKee,
2006).
In a recent article. Miller, Moore, and Strang (2006) discussed the im-
portance of limiting the influence that funding bodies can exert over the
design, analysis, and dissemination of research. They highlighted the role
that major funding bodies (such as pharmaceutical companies, the alcohol
and tobacco industries, and government departments) can have in influ-
encing research findings and the dissemination of those findings. This was
argued to be important from two angles: (1) keeping true to the ideals of
science, and (2) adhering to the ethical principle of beneficence. Both have,
to some degree, been encapsulated in the introduction above. They con-
cluded with recommendations specific to the research community, joumal
editors, and members of ethics committees. These recommendations focus
mostly around academic journals using more comprehensive conflict-of-
interest statements. The article has generated significant debate within the
academic community and subsequent commentaries have added substan-
tially to our knowledge of the nature and extent of funding body regulation
of research (Ashcroft, 2006; Cvetkovski & Fry, 2006; Hall, 2006a; Hall,
2006b; Hough & Tumbull, 2006; Khoshnood, 2006; Lenton & Midford,
2006).
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TYPES OF REGULATION
Miller et al. (2006, p. 12) identified five major avenues through which
funding bodies regulate research. These were: direct censorship (where
material is edited or dissemination is interfered with); limiting access to
data (restricting access to unfavorable data or making access conditional
upon favorable reporting); ongoing funding insecurity (attaching condi-
tions to subsequent funding if previous findings have been awkward or
unwelcome); using underqualiñed or easily influenced researchers (which
allows funders to control the quality of investigation being carried out,
even before the research has commenced); and setting research agendas
(whereby decisions are based on the political, financial, or ideological in-
terests of the funding body, creating a "publication bias" in the knowledge
base). Some are more subtle than others but not necessarily less intrusive.
Lenton and Midford (2006) point to the contracting of research through
"commissioning" as the major issue facing researchers. They propose that
commissioning practices—when govemments or other funding bodies that
can control the types of research being done will come to dominate the
evidence base with findings—will result in a literature base that does not
reflect reality. Hough and Tumbull (2006) support this point, particularly
within the context of competitive tendering and "contract research," which
hands larger organizations, who have already demonstrated compliance
with funding body agendas, substantial advantage in terms of economies
of scale and the resources they are able to bring to the table.
For example, pharmaceutical companies might create a "publication
bias" by oversubscribing to studies that examine the efficacy of pharma-
cotherapeutic solutions to drug-related problems, which will result in the
evidence base appearing to be overly favorable for such an intervention
(Babor & McGovem, 2004). A study of conflict of interest in medical
research pointed out that in the United States "Pharmaceutical compa-
nies spent approximately $23 billion on clinical research in 2001 as com-
pared with $18 billion from the National Institute of Health" (Friedman &
Richter, 2004, p. 55). They found that researchers with conflict of interest
are more likely to present positive findings and more worryingly, there
was only one instance of negative findings being published by researchers
who were supported by private funders (Friedman & Richter, 2004). In
other words, the pharmaceutical industry produces more evidence than
any other source, and it is almost entirely supportive of pharmaceutical
solutions to health-related problems. This represents a substantial skewing
of the evidence base toward their products.
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Pliarmaceutical companies are not alone. Smali et ai. (2006) point out tiie
difficulty in obtaining funding for research into tiie effectiveness of needie
and syringe programs (NSPs), and the way in which the U.S. National In-
stitute of Drug Abuse (NIDA) does not give grants to harm reduction. They
report senior scientists' beliefs that whiie evidence supports the efficacy of
NSPs, the U.S. government wiii not fund research into their effectiveness,
or indeed the more important topic of how to improve their effective-
ness on what actuaily constitutes modeis of best practice (Poliaic, 2007).
Such a iack of research can iead to the sicewing of meta-anaiyses and give
rise to inaccurate conclusions regarding the effects of such interventions
(see Amundsen, 2006). This goes further when considering funding poiiti-
caiiy expedient interventions, the most notabie exampie of which is "drugs
education" (Foxcroft, 2005). Whiie such programs are easy for interested
parties (such as politicians, tobacco, and aicohol companies [Room, 2005J)
to point to as exampies of action and have a "common-sense" element, the
programs have consistently shown little, if any, effect, even in ideal cir-
cumstances (Hawthorne, 2001). The most salient example of this is the
support of life skills training (LST) programs by tobacco companies and
how the industry used research to support the position, long after it was
found ineffective (Wakefield et al., 2006). Mandel (2006) documents the
long history of how, despite continued evidence of the lack of effective-
ness of such campaigns, tobacco companies have persistently focused on
education as a way to reduce smoking-related illness, recruiting amenable
researchers with very large sums to come up with the latest variation and
propose further research when it is found unsuccessful. At worst this is
a skewing of the knowledge base toward interventions that focus on the
individual. At best it is a comparatively cheap campaign to improve the
image of tobacco companies (Action on Smoking and Health, 2007).
These types of issues become even more important when considering
how an interested party can employ the current evidence base and uncritical
academics to bolster their positions. There are many examples, but two very
recent ones stand out: the DrinkWise trust in Australia (one could also look
at the United Kingdom's Drinkaware trust), and a recent book and pamphlet
released by the Intemationai Center for Alcohol Policies (ICAP) (Stimson,
2006; Stimson et al., 2006). DrinkWise was reportedly established to raise
awareness of alcohol misuse and change drinking culture in Australia. The
organization receives millions of dollars from the alcohol industry, whose
representatives make up half of its 12-member board, while asserting it is
independent. It also received $5 million in Australian Federal Government
funding in 2006. DrinkWise has consistently come under fierce criticism
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from researchers and practitioners for failing to ever engage with major
issues such as sponsorship, advertising, and increasing taxation.
ICAP is an American public relations group funded by the alcohol in-
dustry. It defines its task as "changing the debate about alcohol's place
in the world by shifting the discussion from the commodity to the be-
havior" (Room, 2005, p. 1803). It aims to shift debate from policy-level
interventions (which are most likely to affect their financial bottom line) to
those that place all responsibility on the individual drinker (Room, 2005).
Despite ICAP's veneer of scientific objectivity, and its claims of being a
go-between that can bring together the different constituencies in the world
of alcohol policy, their work has been identified as an ideological instru-
ment on behalf of an industry with deeply vested interests that has consis-
tently twisted the scientific process to suit their own purposes (Foxcroft,
2005).
Both of these organizations purport to be interested in the common
good but consistently fail to focus on the major influences that they wield
in regard to alcohol consumption, namely advertising, sports sponsorship,
and outlet density. As Room notes, these bodies have "an aversion to
identifying the product as a source of problems; instead, in the industry's
view, the focus should be on the drinker" (Room, 2005, p. 1803).
OTHER INTEREST GROUPS
Funding bodies are not the only groups to control research findings.
For example. Hall (2006b) identified the possibility of drug user groups
and socially conservative members of ethics committees placing priority
on their own interests above the integrity of the research. In a subsequent
commentary. Hall (2006a) also points out that there is substantial room for
conflict of interest inherent in the current peer review framework. He notes
that with increasing competition over scarce resources, individuals may
thwart the publication of research papers from their major competitors for
funding, or papers that counter their own theories or findings. It may be
that we should be looking at reviewers, and even journal editors, supplying
ethical statements as well.
Other social groups who might seek to influence research might in-
clude, fellowship groups who do not permit research into their groups,
professional associations, religious organizations, and even service
providers. Where some fellowship groups may influence research find-
ings through nonparticipation, professional associations (such as medical
Peter G. Miller 53
societies) have traditionally sought to maintain or increase their influence
regarding any number of areas of knowledge and practice (Wiliis, 1989).
Each discipline produces its own literature base, and the size and compiex-
ity of this iiterature base heips to determine differential power structures
within treatment settings. In the AOD sector, medicine (with the support of
the vast pharmaceutical industry) dominates the literature base, resulting in
the medical model (and phannacotherapies) having the strongest evidence
base.
The role that religion plays in the AOD sector is complex and requires
a body of work in its own right. However, some religious organizations
and individuals have clearly acted to influence the knowledge base. The
best-known example of this was the "witch hunt" conducted in 2003 in
the United States, initiated by conservative political and religious groups
(Khoshnood, 2006). Organizations such as the Traditional Values Coali-
tion (a conservative advocacy group) used public databases to create a list
of 198 "morally questionable" U.S. government funded research projects
involving men who have sex with men, drug users, and sex workers in
HIV prevention (Kaiser, 2003). Specific examples include research into
HIV prevention in injecting-drug users in Russia and condom use in teens.
Members of the U.S. congress were asked to stop funding of these projects,
despite them already having been funded and having cleared rigorous sci-
entific review (CBS News, 2003). The main objection of these ideologically
driven conservative groups was that they considered the research immoral.
Such behavior has very substantial implications for the integrity of the
knowledge base and could easily mean that effective interventions for HIV
prevention or AOD treatment will not be investigated or implemented.
Of course, this situation already exists in regard to the Catholic Church's
campaign against condoms in Africa and the U.S. Agency for Interna-
tional Development's (USAID) position on NSPs and abstinence-only sex
education (Trenholm et al., 2007).
AOD-related treatment providers are also not disinterested parties. All
derive their incomes (and some of their raison d'etre) from the service
they provide. This has substantial implications for the politics of treatment
and the vested interest that many people bring to the research table. The
political and economic weight of mantras such as "treatment works" bear
little relation to the complex evidence base and far more to the pragmatic
needs of governments and service providers. While many service providers
use discourses of charitable objectives, they are invested both financially
and existentially in the perceived success of the treatment they provide.
Such issues require that leaders within the field continue to apply a strong
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critical gaze to research and encourage an ethos of independence, even
when it may not be economically prudent.
ISSUES BEYOND TREATMENT EFFECTIVENESS
The vast majority of the literature base in the AOD sector is focused
on the effectiveness of different interventions or the individual risk factors
for substance use. Much of the evidence base is driven by interest groups
focused on technological fixes (such as vaccines), individual-based ther-
apies, and to a lesser degree, public health measures. Though important,
these interventions ultimately fail to act on some of the overwhelming
factors that continually show up as major factors in the etiology of prob-
lem drug use, such as relative deprivation and social exclusion (Stafford
& Marmot, 2003). Whatever one's theories or beliefs about the etiology
of drug-related problems, the role of sociodemographic factors are usually
ignored as the "elephant in the room" (Shaw et al., 2007). Socioeconomic
status, declining social cohesion, mental health problems, hopelessness,
and the breakdown of family units have all been shown to be powerful
predictors of problematic drug use and yet the vast majority of the inter-
ventions for drug-related problems are based on the individual (e.g., Rehm,
Taylor, & Room, 2006). While this can be partially explained away through
assertions that individual-based therapies are far more easy to implement
and almost certainly much cheaper, it may well be that the net result of
using individual-focused therapies alone is mediocre success rates and
the individual being held responsible for failure, rather than the treatment
system and culture (Shaw et al., 2007).
THE IMPACT OF SOCIAL SYSTEMS
ON ADDICTION AND RECOVERY
One of the most forgotten truisms within the sector is that different
cultures see drug use and its associated benefits and consequences very
differently. Treatment and intervention regimes often run in parallel with
the ideologies that inform social welfare systems, health policy, and crim-
inal justice systems. Where many politicians, commentators, and interest
groups focus on drug policy and the different ideologies and structures of
different country's drug treatment systems, the reality is that drug policy
remains a very small part of a very big picture, which includes elements
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such as macroeconomic trends, changes in the urban landscape, migration
trends, and cultural responses to such issues (Babor et al., 2003). Ulti-
mately, the phenomenon of drug-related problems is, in fact, a myriad of
outcomes and etiologies defined by the single common element of drug
involvement. Yet, this remains in the background of current thinking sur-
rounding AOD problems, denying the reality that social systems have a
far greater impact on addiction and recovery than many attribute in their
day-to-day lives.
For example, in Sweden, a very wealthy country with almost no mi-
gratory influences and a strong history of highly developed social welfare
systems, drug policy is viewed as part of its welfare and social policy.
Drugs are seen as one of their most serious social problems and an external
menace to the country (Lenke & Olsson, 2002). Within this context it is cul-
turally acceptable for the state to have an interventionist approach to health,
which includes coercive treatment for drug use alone. On the other hand,
in the United States, where social welfare systems are far less intrusive
and primarily based around individual autonomy and responsibility, treat-
ment systems are far less intrusive at the drug-treatment level (Maxwell,
2001). Treatment episodes are primarily privately funded through health
insurance companies, though the state does provide some treatment.
Countries also differ substantially depending on how governments frame
the issue in terms of being a criminal or a health issue. In Britain, drug
dependence is seen as being a public issue because of the crime it "causes"
(McSweeney, Stevens, Hunt, & Tumbull, 2007). Therefore, the Home Of-
fice (responsible for policing, criminal justice, and state security) plays
a major role in the funding of treatment and formation of policy. On the
other hand, Australia views drug use primarily as a public health issue
(although the majority of spending still goes to law enforcement). Treat-
ment funding has traditionally come from government health departments,
though there is a small private sector (National Drug Strategy [Australia],
1994). However, in both of the previous examples, the lines are becoming
increasingly blurred because of the worldwide uptake of criminal justice-
funded treatment programs as alternatives to prison (McSweeney et al.,
2007).
Importantly, as cultures can change over time, so can the way com-
munities and governments perceive and deal with drug-related problems.
This is particularly the case as political parties gain and lose power. An
example of this can be seen in Australia, which has seen substantial
systemic changes in the culture of dealing with drugs over the past 10
years since the conservative Liberal party took power from the more left
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Labour Party. Harm reduction in Australia was started by a Labour gov-
emment in the mid-1980s and had traditionally been unpopular with the
Liberal conservatives. On taking government in 1996, the Liberal party
found it difficult to change policies quickly due to the evidence base in
Australia having been overwhelmingly supportive of harm-reduction in-
terventions. This literature base was developed by independent researchers
from academic traditions. Over 10 years, the Liberal govemment has had
a policy of disempowering independent academic critique across a wide
range of public policy areas, using both the control of funding to uni-
versities and discursive campaigns that undermine the credibility of all
academics. This is exemplified in their policy approach to drugs, aptly
named "Tough on Drugs," developed primarily as a response to academic
and political support for a prescription heroin trial (Bammer, 1996). This
policy environment has seen most independent research either defunded
or moved under the control of govemment departments. The policy ob-
served within this regime is that official documents have not been allowed
to use the words "harm reduction," meaning that even engaging in dis-
cussions about how best to reduce the harm associated with drugs has
required a different language. Alongside this there has been the abolition
of many professional advisory committees (removing many of the voices
in support of harm reduction at the same time) and massively increased
targeted funding specifically for residential rehabilitation facilities, which
have traditionally not demonstrated cost effectiveness within the Australian
context.
The biggest changes in culture and social systems also affect the is-
sues that impact on drug use and its associated problems. Trends such as
"globalization" and "consumerism" bring changing problems, and require
more current and honest research. Consumerism helps fuel the develop-
ment of new drug types, or new ways of taking old drugs (Fischer & Rehm,
2007). Globalization (and particularly the advent of the Intemet) means
that these trends spread almost instantaneously and traditional boundaries
(social/geographical/cultural) are no longer effective in slowing or halting
changing trends in drug use. Research struggles to keep up with such de-
velopments and when highly stigmatized harms are associated with these
drug-use patterns, political and social norms can often try to influence the
conduct and dissemination of research. Not-too-distant memories of suc-
cessive govemments denying the presence of HIV/AIDS in their country
and the emergence of the consequences of such denials remind us of the
importance of ideologically and financially independent research cultures.
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CONCLUSION
"Reflection and conversation are at the heart of ethical dialogue in
any setting" (McGovem et ai., 2004, p. 105).
There are many ways in which the coiiective knowiedge base can be influ-
enced by interest groups with their own agendas. There is an implicit need
within the AOD sector for researchers and clinicians to practice critical
self-reflection. The most reliable method of doing so is the conduct and
dissemination of rigorous independent research. The valuing of "critical
friends," whether they be researchers, other clinicians, or service users, is a
vital ethos, which all of us who deal with addiction-related problems have
a duty to encourage. We should also show healthy skepticism when assess-
ing the motives of different interest groups, whether they are service users,
poiiticians, or big pharmaceutical corporations. The collective knowledge
base of all who work within the AOD sector is a resource for which all
parties must accept responsibility to keep free of bias. As McGovem et al.
suggest it is vital that we, as a discipline, keep openly and honestly debating
those things we find most challenging.
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